ten23 health acquires swissfillon
Deal provides ten23 with drug product development, biologic manufacturing experience
swissfillon, who specializes in sterile filling of pharmaceuticals, is joining ten23 health, a Swiss contract development and manufacturing organization (CDMO) that recently launched this past September.
The acquisition of swissfillon—an FDA and Swissmedic approved CDMO also based in Switzerland—is expected to deliver an offering for sterile drug product development and manufacturing of biologics, molecules and dosage forms, the parties note. Prof. Dr. Hanns-Christian Mahler will serve as CEO of the combined entities under the ten23 health umbrella. Daniel Kehl, founder of swissfillon, will remain with the business in a leadership position, helping to run ten23’s new infrastructure engineering projects that occur under the partnership.
“ ... Sterile fill-and-finish services are expected to experience significant growth over the coming years,” says Hanns-Christian Mahler, CEO of ten23 health. “This rising demand is driven by expanded drug development pipelines, incorporating more complex, large-molecule products and therapies that require specific expertise for both development and sterile production. This is precisely why we expect ten23 health’s services, now including swissfillon, to be in great demand.”
